Fraiser Kansteiner

Fraiser Kansteiner, a journalist from Fierce Pharma, joins to unravel the fierce competition between Novo Nordisk and Eli Lilly in the obesity drug market. They discuss Novo's challenges, including product shortages and a recent pipeline clearout. Kansteiner highlights Lilly’s successful strategies amidst increasing sales and the implications of compounding pharmacies. The conversation also touches on Pfizer's exit from the obesity race and the potential emergence of smaller biotech firms, painting a vivid picture of the evolving landscape.